Table 1 Patient demographics and clinical outcomes.
From: Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma
Demographics | All patients (N = 60) | BM-MRDneg (N = 47) | BM-MRDpos (N = 13) | P- Value |
|---|---|---|---|---|
Age (year), median (range) | 62 (34–81) | 62 (41–81) | 60 (34–70) | 0.3 |
Male, n (%) | 32 (53) | 23 (49) | 9 (69) | 0.2 |
Median time from initial diagnosis to CAR-T evaluation, year, median (range) | 6 (0–15) | 6 (0–15) | 6 (0–15) | 0.7 |
High risk cytogenetic profile, n(%) | 28 (70)* | 21 (70) | 7 (70) | 1 |
ISS Stage II/III, n (%) | 14 (31) | 11 (31) | 3 (30) | 0.9 |
ECOG ≥ 1, n (%) | 17 (31)** | 12 (29) | 5 (39) | 0.5 |
Bridging therapy, n (%) | 46 (77) | 39 (83) | 7 (54) | 0.03 |
Prior lines of therapy, median (range) | 5 (2–17) | 5 (2–12) | 6 (2–17) | 0.09 |
Plasmacytoma, n(%) | 23 (38) | 17 (36) | 6 (46) | 0.7 |
Clinical outcome | ||||
Cytokine release syndrome, all grade, n (%) | 45 (75) | 36 (77) | 9 (69) | 0.6 |
ICANS, all grade, n(%) | 13 (22) | 11 (23) | 2 (15) | 0.5 |
Tocilizumab use, n(%) | 25 (42) | 22 (47) | 3 (23) | 0.1 |
Steroid use, n(%) | 15 (25) | 13 (28) | 2 (15) | 0.4 |
Cumulative dexamethasone dose, mg, median (range) | 20 (10–1309.6) | 20 (10–1309.6) | 25 (10–40) | 1 |
Anakinra use, n(%) | 5 (8) | 5 (10.6) | 0 (0) | 0.2 |
Month 1 response, CR/sCR, n (%) | 10 (17) | 10 (21) | 0 (0) | 0.07 |
Best response- CR/sCR, n (%) | 27 (45) | 27 (57) | 0 (0) | <0.001 |
FLC < normal, n (%) | 43 (72) | 40 (85) | 3 (23) | <0.001 |
